The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients
Ze Jin,Yi Miao,Jie Zhang,Jing Zhang,Chunling Wang,Xuzhang Lu,Yuqing Miao,Miao Sun,Yunping Zhang,Yun Zhuang,Haiwen Ni,Jingyan Xu,Wanchuan Zhuang,Min Zhao,Jianfeng Zhu,Min Xu,Guoqiang Lin,Haiying Hua,Xiaoyan Xie,Maozhong Xu,Tao Jia,Lijia Zhai,Weiying Gu,Qiurong Shan,Zhi Wang,Qiudan Shen,Xiaohui Zhang,Jianyong Li,Wenyu Shi
DOI: https://doi.org/10.1007/s00277-024-05631-0
2024-01-25
Annals of Hematology
Abstract:To investigate the prognostic impact of serum beta-2 microglobulin (B2M) in adult lymphoma-associated hemophagocytic lymphohistiocytosis (HLH). The clinical and laboratory characteristics of 326 adult patients in a multicenter cohort with lymphoma-associated HLH with available baseline serum B2M levels were retrospectively analyzed. A total of 326 cases were included in this study, and the median serum B2M level was 5.19 mg/L. The optimal cut-off of serum B2M was 8.73 mg/L, and the cases with serum B2M level >8.73 mg/L were older and had a more advanced stage, lower levels of platelets, albumin, and fibrinogen, and higher creatinine level. The serum B2M >8.73 mg/L, creatinine ≥133 μmol/L, fibrinogen ≤1.5 g/L, agranulocytosis (<0.5 × 109/L), severe thrombocytopenia (<50 × 109/L), and high Epstein–Barr virus DNA copy number were found to have independent prognostic values in all patients, and the serum B2M >8.73 mg/L was also an independent prognostic factor in patients with creatinine <133 μmol/L. Finally, a prognostic scoring system was established based on independent prognostic factors of all patients and categorized the patients into three groups with significant prognostic differences. This study confirmed that the serum B2M level can be an independent prognostic factor in lymphoma-associated HLH and established a prognostic scoring system to predict patients’ survival.
hematology